Conference Posters

Below you can access Liminal’s abstracts and scientific posters. Please note that some abstracts and posters may refer to Liminal BioSciences’ previous name Prometic Life Sciences Inc.

  • PBI-4547 Restores Metabolic Homeostasis in a High Fat Diet Model of Non-Alcoholic Fatty Liver Disease

    PBI-4547 Restores Metabolic Homeostasis in a High Fat Diet Model of Non-Alcoholic Fatty Liver Disease

    Read PDF
  • PBI-4050 reverses metabolic dysregulation induced by a high fat diet

    PBI-4050 reverses metabolic dysregulation induced by a high fat diet

    Read PDF
  • PBI-4050 promotes hepatic stellate cell autophagymitophagy and restores a quiescent-like phenotype

    PBI-4050 promotes hepatic stellate cell autophagymitophagy and restores a quiescent-like phenotype

    Read PDF
  • PBI-4050 Reduces Renal Injury in a Mouse Model of Aristolochic Acid-Induced Nephropathy

    PBI-4050 Reduces Renal Injury in a Mouse Model of Aristolochic Acid-Induced Nephropathy

    Read PDF
  • PBI-4050 Reduces Systemic Inflammation, Electrolyte Disturbances and Renal Injury in Mice with Sepsis-induced Acute Kidney Injury; Role of G

    PBI-4050 Reduces Systemic Inflammation, Electrolyte Disturbances and Renal Injury in Mice with Sepsis-induced Acute Kidney Injury; Role of G

    Read PDF
  • Fatty Acid Receptors GPR40/GPR84: Two Promising Targets in Kidney Fibrosis

    Fatty Acid Receptors GPR40/GPR84: Two Promising Targets in Kidney Fibrosis

    Read PDF
  • PBI-4050 Improves Metabolic Regulation and Diabetic Nephropathy through Reduction of ER Stress, Pro-Inflammatory/Fibrotic Markers, Galectin-

    PBI-4050 Improves Metabolic Regulation and Diabetic Nephropathy through Reduction of ER Stress, Pro-Inflammatory/Fibrotic Markers, Galectin-

    Read PDF
  • Activation of the Free-fatty Acid Receptor GPR40 Improves Anemia in Mouse Models of Kidney Disease Via a Novel EPO-Independent Mechanism of

    Activation of the Free-fatty Acid Receptor GPR40 Improves Anemia in Mouse Models of Kidney Disease Via a Novel EPO-Independent Mechanism of

    Read PDF
  • PBI-4050 reduces systemic inflammation, electrolyte disturbances and renal injury in mice with sepsis-induced acute kidney injury

    PBI-4050 reduces systemic inflammation, electrolyte disturbances and renal injury in mice with sepsis-induced acute kidney injury

    PBI-4050 exerts anti-inflammatory and anti-fibrotic effects in several diabetic and non-diabetic models of kidney injury through modulation of GPR40 and GPR84 fatty acid receptors.

    Read PDF
  • Activation of the Free-Fatty Acid Receptor GPR40 Improves Anemia in Mouse Models of Kidney Disease via a Novel EPO-Independent Mechanism of

    Activation of the Free-Fatty Acid Receptor GPR40 Improves Anemia in Mouse Models of Kidney Disease via a Novel EPO-Independent Mechanism of

    The prevalence of anemia increases with the progression of chronic kidney disease (CKD), and leads to reduced quality of life and increased cardiovascular risk.

    Read PDF
  • PBI-4050 decreases adenine-induced tubulointerstitial injury and er-stress; implications of the GPR40 receptor

    PBI-4050 decreases adenine-induced tubulointerstitial injury and er-stress; implications of the GPR40 receptor

    The aim of this study was to further examine the effects of PBI-4050 in both WT and GPR40 activation-/- mice on adenine-induced tubulointerstitial injury, anemia and the unfolded protein response path

    Read PDF
  • PBI-4547 Prevents Progression of Prediabetic Condition to Type 1 Diabetes in NOD Mice

    PBI-4547 Prevents Progression of Prediabetic Condition to Type 1 Diabetes in NOD Mice

    PBI-4547 administration in prediabetic type 1 NOD mice significantly prevented the evolution to severe diabetes resulting in increased survival.

    Read PDF
  • PBI-4547 Improves Glucose Metabolism and Insulin Resistance, and Reduces Liver Damage in a High-Fat Diet Mouse Model of Obesity and Metaboli

    PBI-4547 Improves Glucose Metabolism and Insulin Resistance, and Reduces Liver Damage in a High-Fat Diet Mouse Model of Obesity and Metaboli

    Taken together, these results suggest that PBI-4547 offers the potential as a novel therapy for Non-alcoholic fatty liver disease (NAFLD), obesity, type 2 diabetes mellitus, and associated metabolic s

    Read PDF
  • PBI-4050 Improves Metabolic Regulation and Diabetic Nephropathy through Reduction of ER Stress, Pro-Inflammatory/Fibrotic Markers, Galectin-

    PBI-4050 Improves Metabolic Regulation and Diabetic Nephropathy through Reduction of ER Stress, Pro-Inflammatory/Fibrotic Markers, Galectin-

    These results suggest that PBI-4050 is a strong potential candidate for the treatment of metabolic diseases and related diabetic nephropathy.

    Read PDF
  • PBI-4547 Reverses Diabetes and Metabolic Syndrome through Regulation of Lipid/Glucose Metabolism

    PBI-4547 Reverses Diabetes and Metabolic Syndrome through Regulation of Lipid/Glucose Metabolism

    PBI-4547 reduces Blood glucose, cholesterol and triglycerides levels, Pro-inflammatory and pro-fibrotic markers in liver, Adipocyte size and fibrosis in WAT

    Read PDF
  • loading
    Loading More...